ADVOCACY

Position Statements & Letters

The AMP advocacy program endeavors to inform and influence public policy affecting molecular pathology. AMP represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues - reaching out to fellow professional associations, industry and other association partners to accomplish common goals. Position statements, comments, and letters are usually generated by our Professional Relations and Economic Affairs Committees, though our Clinical Practice and Training & Education Committees do advocate in their areas.

We invite you to explore AMP's Position Statements and Communications. For more information, please contact Mary Williams.

2018 Title Keywords Committee
October 22 Comments on the Preliminary Determinations for Calender Year 2019 for New and Reconsidered Services on the Clinical Laboratory Fee Schedule CMS, CLFS, Preliminary Determinations Economic Affairs
September 10 Comments on the CY2019 Physician Fee Schedule Proposed Rule PAMA, CMS, CLFS, PFS Professional Affairs
August 8 Joint Comments on Draft Local Coverage Determination - Biomarker Testing for Prostate Cancer Diagnosis (DL37733) LCD, MAC, DL37733, Biomarker Professional Affairs
August 7 Comments on the 2018 Preliminary Gapfill Payment Determinations for CY2019 CMS, CLFS, gapfill, PAMA, GSP Professional Affairs
August 24 Comments on FDA's technical assessment of the Diagnostic Accuracy and Innovation Act LDP, LDT, DAIA, CLIA, CMS, FDA, IVD Professional Affairs
June 25 AMP Crosswalk Recommendations to CMS for New and Reconsidered CPT Codes CMS, CPT, CLFS Professional Affairs
June 21 Stakeholder Sign On letter for Laboratory Testing Oversight  LDP, LDT, DAIA, CLIA, CMS, FDA, IVD Economic Affairs
June 11 Joint Comment Letter on MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels (DL37764) LCD, MAC, DL37764, ID Economic Affairs
June 11 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification Tests (NAATs) (DL37766) LCD, MAC, DL37766, NAATs, ID Economic Affairs
June 11 Joint Comment Letter on Draft Local Coverage Determination: MolDX: MDS FISH (DL37772) LCD, MAC, DL37772, FISH, MDS Economic Affairs
June 11 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Colorectal Cancer (DL37222) LCD, MAC, DL37222, CGP Economic Affairs
June 11 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Melanoma (DL37220) LCD, MAC, DL37220, CGP Economic Affairs
June 11 Joint Comment Letter on MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Advanced Primary Peritoneal, Fallopian tube and Ovarian Cancer (DL37203) LCD, MAC, DL37203, CGP Economic Affairs
May 10 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Advanced Primary Peritoneal, Fallopian Tube and Ovarian Cancer (DL37723) LCD, MAC, DL37723, CGP Economic Affairs
May 10 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Colorectal Cancer (DL37719) LCD, MAC, DL37719, CGP Economic Affairs
May 10 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification Tests (NAATs) (DL37709) LCD, MAC, DL37709, ID, NAATs Economic Affairs
May 10 Joint Comment Letter on MolDX: MDS FISH (DL37602) LCD, MAC, DL37602, FISH Economic Affairs
May 10 Joint Comment Letter on Draft Local Coverage Determination: MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Melanoma (DL37721) LCD, MAC, MolDX, CGP, NGS, DL37721 Economic Affairs
May 10 Joint Comment Letter on MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels (DL37713) LCD, MAC, ICD-10 Economic Affairs
April 11 Joint Comments to Proposed LCD for Molecular Pathology Procedures (DL35000) CAP, LCD, MAC Economic Affairs
April 11 AMP-CAP Comments to Local Coverage Determination Regarding Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (DL37606). CAP, LCD, MAC, NGS, MDS, MPN, AML, CPT, ICD-10 Economic Affairs
April 11 AMP Comments to Local Coverage Determination Regarding Administrative Multianalyte Assays with Algorithmic Analyses (MAAA) and Proprietary Laboratory Analyses (PLA) Services (DL37600). MAAA, PLA, CPT, MAC, LCD Economic Affairs
March 28 AMP and CAP Comments to MolDX: Guardant360 Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) (DL37671) LCD, NSCLC, CPT, MAC Economic Affairs
March 23 AMP Comments to North Carolina Medicaid and NC Health Choice Program coverage of genetic testing for susceptibility to breast and ovarian cancer North Carolina, FORCE, NothingPink, BRCA, Medicaid Professional Relations
March 19 AMP Comments to Docket No. FDA-2017-N-6356, Investigational In Vitro Diagnostics Used in Clinical Investigations of Therapeutic Products; Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards FDA, LDP, IVD, CLIA, CMS, IDE, NIH Professional Relations
March 12 AMP Comments to Revisions to Personnel Regulations, Proficiency Testing Referral, Histocompatibility Regulations and Fee Regulations under the Clinical Laboratory Improvement Amendments of 1988 (CLIA); CMS-3326-NC CMS, CLIA, RFI Professional Relations
January 25 Request for Information on Promoting Healthcare Choice and Competition Across the United States CMS, NGS, MolDx, MAC, NCA, PAMA, LCD Economic Affairs
January 17 Comments to CMS for Proposed Decision Memorandum on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG #00450N) NGS, CMS, NCA, FDA, F1CDx, IVD, NCD, LDP Economic Affairs

Corporate Partners